On April 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to alpelisib (Vijoice) for adult and pediatric patients aged 2 years and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. PROS encompasses a group of rare disorders that cause overgrowth of parts of the body, due to mutations in the PIK3CA gene.
Efficacy was evaluated using real-world data from EPIK-P1, a single-arm clinical study in patients aged 2 years and older with PROS who received alpelisib as part of an expanded-access program for compassionate use. Eligible patients had clinical manifestations of PROS that were assessed by the treating physicians as severe or life-threatening and necessitating systemic treatment, and also had documented evidence of mutation in the PIK3CA gene.
The efficacy of alpelisib was evaluated in a total of 37 patients with at least one target lesion identified on imaging performed within 24 weeks prior to receipt of the first dose. The major efficacy outcome measure was the proportion of patients with a radiologic response at week 24 as determined by blinded independent central radiology review, defined as a ≥ 20% reduction from baseline in the sum of measurable target lesion volume in up to three lesions, confirmed by at least one subsequent imaging assessment. Duration of response was an additional efficacy outcome measure.
Of the 37 patients included in the efficacy population, 27% (95% confidence interval = 14%–44%) had a radiologic response at week 24. Among responding patients, 60% had a response lasting 12 months or longer. The most common (≥ 10%) adverse reactions occurring in patients were diarrhea, stomatitis, and hyperglycemia.
The recommended alpelisib dosage for pediatric patients (aged 2 years to less than 18 years) is 50 mg taken orally once daily with food; for pediatric patients aged 6 years and older, the dose can be increased to 125 mg after 24 weeks if clinically indicated. The recommended dosage for adult patients (≥ 18 years) is 250 mg taken orally once daily with food.
This review used the Real-Time Oncology Review pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.
This application was granted Priority Review, Breakthrough Therapy designation, and Orphan Drug designation.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.